Work

453MO A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.523

Authors: W. Li, Z. Kang, S. Li, F. Chen, B. Zhang, M. Huang, Z. Yang, C. Chen, Z. Yang

Institutions: Capital Medical University, Beijing Tian Tan Hospital

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Gilead Sciences, Astellas Pharma, Astellas Pharma Europe, Sociedad Española de Oncología Médica, Daiichi Sankyo Europe

OpenAlex ID: W4402561345

FWCI:

Cites:

Cited by:

Related to: 10